161669 20251017144612.0 doi 10.1007/s00415-025-13177-y sideral 144321 ART-2025-144321 eng García-Castillo, María Clara Concomitant anti-CGRP and immunomodulatory treatments in patients with migraine: towards integrated management strategies 2025 Access copy available to the general public Unrestricted Preclinical evidence supports the immunoregulatory role of calcitonin gene-related peptide (CGRP) in migraine pathophysiology. The increasing use of anti-CGRP therapies in patients with migraine and other comorbidities raises the question whether the potential use of anti-CGRP monoclonal antibodies (CGRP-mAbs) therapies in combination with other immunological therapies is effective and safe. Methods. This multicenter study included patients with migraine receiving CGRP-mAbs combined with immunosuppressive and immunomodulatory treatments. Clinical and demographic data, treatment history, laboratory markers and treatment-emergent adverse events (TEAEs) were analyzed. Effectiveness outcomes included the change in monthly migraine days (MMD) and monthly headache days (MHD) at 3, 6, 9 and 12 months, alongside the > 50% response rate. Moreover, autoimmune disease progression was also evaluated. We explored differences between patients with and without autoimmune disease activation. Results.Among 89 patients, there were 80 (90%) females with a mean age of 50 years (SD: 11), who had a high prevalence of psychiatric comorbidities (anxiety 44%, depression 49%) and medication overuse (68%). Patients receiving immunological treatments experienced significant reductions in MMD and MHD, with MMD decreasing from 16 (SD: 7) at baseline to 9 (SD: 8) at 6 months, and MHD dropping from 23 (SD: 8) to 17 (SD: 11). A 50% response in MMD was achieved by 46% at 6 months. TEAEs were reported in 28%, most commonly constipation (16%) and dizziness (9%). Conclusions. CGRP-mAbs therapies combined with immunological treatments appear effective and safe in patients with autoimmune diseases. Larger prospective studies are necessary to confirm these findings and optimize management strategies. info:eu-repo/grantAgreement/ES/ISCIII/CM21-00178 info:eu-repo/grantAgreement/ES/ISCIII/JR23/0005 info:eu-repo/grantAgreement/ES/ISCIII/PI24-01085 info:eu-repo/semantics/openAccess by https://creativecommons.org/licenses/by/4.0/deed.es info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Sierra-Mencía, Álvaro Caronna, Edoardo Toledo-Alfocea, Daniel Jaimes, Alex Urtiaga, Saray Casas-Limón, Javier Muñoz-Vendrell, Albert Santos Lasaosa, Sonia Universidad de Zaragoza (orcid)0000-0001-5139-6031 García Martín, Valvanuz Martín Ávila, Guillermo Polanco, Marcos Villar-Martínez, Maria Dolores Trevino-Peinado, Cristina Rubio-Flores, Laura Sánchez-Soblechero, Antonio Portocarrero Sánchez, Leonardo Luque-Buzo, Elisa Lozano-Ros, Alberto Gago-Veiga, Ana Beatriz Díaz-De-Terán, Javier Recio García, Andrea Canales Rodríguez, Javiera Gómez García, Andrea González Salaices, Marta Campoy, Sergio Mínguez-Olaondo, Ane Maniataki, Stefania González-Quintanilla, Vicente Porta-Etessam, Jesús Cuadrado, María-Luz Guerrero Peral, Ángel Luis Pozo-Rosich, Patricia Rodríguez-Vico, Jaime Huerta-Villanueva, Mariano Pascual, Julio Goadsby, Peter J. Gonzalez-Martinez, Alicia 1007 610 Universidad de Zaragoza Dpto. Medicina, Psiqu. y Derm. Area Medicina 272, 6 (2025), 12 pp. J. neurol. Journal of Neurology 0340-5354 793323 http://zaguan.unizar.es/record/161669/files/texto_completo.pdf Versión publicada 2523026 http://zaguan.unizar.es/record/161669/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:161669 articulos driver 2025-10-17-14:17:56 ARTICLE